Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


12>>>
50 Items
Title  Creator  Group name  Publishing year 
[68Ga]Ga-FAPI-46 synthesis on a GAIA® module system: Thorough study of the automated radiolabeling reaction conditions Rubira et al. EquipeJPP 2024-04
Towards Optimal Automated 68Ga-Radiolabeling Conditions of the DOTA-Bisphosphonate BPAMD Without Pre-Purification of the Generator Eluate Souche et al. EquipeJPP 2024-11-20
Prognostic Value of 18F-FDG PET/CT Assessment After Radiotherapy of Squamous Cell Carcinoma of the Anus in Patients from the National Multicentric Cohort FFCD-ANABASE Combet-Curt et al. EquipeJPP 2024-08-01
New Drugs for Targeted Radionuclide Therapy in Metastatic Prostate Cancer Hébert et al. EquipeJPP 2024-07
LYMPHOSCORE (Lymphoscintigraphy Scoring Reliability) Reliability of a New Qualitative and Semiquantitative Lymphoscintigraphy Scoring System for Primary Lymphedema Guillemard et al. EquipeJPP 2024-09-01
Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine Hebert et al. EquipeJPP 2024-06-03
"One Method to Label Them All": A Single Fully Automated Protocol for GMP-Compliant 68Ga Radiolabeling of PSMA-11, Transposable to PSMA-I&T and PSMA-617 Fouillet et al. EquipeJPP 2024
Prevention of post-hepatectomy liver failure after major resection of colorectal liver metastases: is hepato-biliary scintigraphy the optimal tool? Cusumano et al. EquipeJPP 3/2023
Identification of 18F-FDG PET/CT Parameters Associated with Weight Loss in Patients with Esophageal Cancer Galvez et al. EquipeAD 2023-07-05
GRECCAR 14 - a multicentric, randomized, phase II-III study evaluating the tailored management of locally advanced rectal carcinoma after a favourable response to induction chemotherapy: Study protocol Rouanet et al. EquipeMY 2023-10
Fc-engineered monoclonal antibodies to reduce off-target liver uptake Mangeat et al. EquipeJPP 2023-09-11
Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case Barakat et al. EquipeJPP 2023-07
Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy Souche et al. EquipeJPP 2023-12-29
225Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic Rubira et al. EquipeJPP 2023-03-24
Unusual Focal Lung Uptake without CT Abnormality on a Bone Scan: What Might It Mean? Eberlé et al. EquipeJPP 2022-04-08
Tailored Media-Fill Test Protocols Inspired by 68Ga Kit-Based Radiopharmaceuticals Donzé et al. EquipeJPP 2022
One-tissue compartment model for myocardial perfusion quantification with N-13 ammonia PET provides matching results: A cross-comparison between Carimas, FlowQuant, and PMOD Nesterov et al. EquipeJPP 10/2022
Myocardial perfusion quantification with Rb-82 PET: good interobserver agreement of Carimas software on global, regional, and segmental levels Nesterov et al. EquipeJPP 06/2022
Lumbosacral Plexus Neurolymphomatosis: A Typical 18FDG PET/CT Pattern to Recognize Bordeau et al. EquipeJPP 4/2022
From the target cell theory to a more integrated view of radiobiology in Targeted radionuclide therapy: The Montpellier group's experience Pouget et al. EquipeJPP 2022
Development and Implementation of a Professional Practices Evaluation during Radiopharmaceuticals Administration Donzé et al. EquipeJPP 2022-11-10
AAZTA-Derived Chelators for the Design of Innovative Radiopharmaceuticals with Theranostic Applications Fersing et al. EquipeJPP 2022-02-16
A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH) Deshayes et al. EquipeJPP 2022-12-22
177 Lu-Dotatate administration using an infusion pump or a peristaltic pump: comparison of two methods Donzé et al. EquipeJPP 2022-09-13
Whole body planar and 3D quantitative imaging after 177Lu-DOTATATE on CZT SPECT/CT device with MEHRS collimator. First report Deshayes et al. EquipeJPP 2021
12>>>
50 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés